A Study of the ReCor Medical Paradise System in Clinical Hypertension
A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 282 participants.
Also called NCT02649426
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 282 participants
- Sponsor
- Registry
-
NCT02649426
-
- Other papers using this trial's data
- Effects of Renal Denervation vs Sham in Resistant Hypertension After Medication Escalation: Prespecified Analysis at 6 Months of the RADIANCE-HTN TRIO Randomized Clinical Trial
- Plasma renin and aldosterone concentrations related to endovascular ultrasound renal denervation in the RADIANCE-HTN SOLO trial
- Renal Artery Variations in Patients With Mild-to-Moderate Hypertension From the RADIANCE-HTN SOLO Trial
- Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Results first posted
- Countries
- United States, Belgium, France, Germany, Netherlands, Poland, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT02649426. Randomized; triple masking; primary purpose treatment. Start 2016-03 (actual); primary completion 2020-09 (actual). Results posted on 2024-06-28.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of the ReCor Medical Paradise System in Clinical Hypertension
- Acronym
- RADIANCE-HTN
- Condition
- Hypertension
- Condition
- Vascular Diseases
- Intervention (Device)
- The Paradise® Renal Denervation Ultrasound System
- Intervention (Device)
- Sham Procedure
- Lead sponsor
- ReCor Medical, Inc.
Record details
- Record id
cardio:ct-nct02649426- Content hash
c1667416bea6586d46d909b2688f285dc49227dcc5300d3bc0a0edd2721ff329